Feb 5, 2026
What are the long‑term safety data for bremelanotide (PT‑141) in women beyond 24 weeks?
Long‑term clinical trial data for (PT‑141) beyond 24 weeks come primarily from a 52‑week open‑label extension of the 24‑week RECONNECT phase‑3 trials—yielding safety information up to a total of 76 we...